Literature DB >> 15722403

Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy.

Marilyn E Morris1, Ke Hu, Qi Wang.   

Abstract

Intoxication with gamma-hydroxybutyric acid (GHB) is associated with coma, seizure, and death; treatment of overdoses is symptomatic. The objectives of this investigation were to characterize the renal clearance and total clearance of GHB in rats and to evaluate potential strategies for increasing the elimination of GHB after drug overdoses. GHB was administered by i.v. infusion at low (108 mg/h/kg), medium (128 mg/h/kg), or high (208 mg/h/kg) doses. Crossover studies were performed under steady-state conditions using the medium dose in the absence or presence of l-lactate, pyruvate, d-mannitol, sodium bicarbonate, or normal saline. GHB in plasma and urine samples was assayed using liquid chromatography-tandem mass spectrometry. Infusion of the low, medium, and high doses of GHB produced steady-state plasma concentrations of 0.22 +/- 0.04, 0.43 +/- 0.05, and 0.68 +/- 0.11 mg/ml. The renal clearance of the medium (51.8 +/- 13.0 ml/h/kg) and high (97.1 +/- 43.1 ml/h/kg) doses was significantly higher than that of the low dose (14.9 +/- 5.1 ml/h/kg), whereas the total clearance values were significantly lower than that of the low dose. The renal clearance was significantly increased by the concomitant administration of l-lactate, pyruvate, d-mannitol, or sodium bicarbonate with GHB but was not altered by normal saline. The total and metabolic clearance values were significantly increased by all treatments except normal saline. Overall, our results indicated that the renal clearance of GHB is dose-dependent, involving capacity-limited reabsorption. Monocarboxylate transport inhibitors, osmotic diuresis using d-mannitol, or the administration of sodium bicarbonate can increase the renal and total clearances of GHB. The approaches used in this investigation may offer potential detoxification strategies for the treatment of GHB overdoses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722403     DOI: 10.1124/jpet.105.083253

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Potential gamma-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation.

Authors:  Indranil Bhattacharya; Kathleen M K Boje
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-08-29       Impact factor: 2.745

2.  An interactive lesson in acid/base and pro-drug chemistry using sodium gamma-hydroxybutyrate and commercial test coasters.

Authors:  Nathaniel A Page; Meaghan Paganelli; Kathleen M K Boje; Ho-Leung Fung
Journal:  Am J Pharm Educ       Date:  2007-06-15       Impact factor: 2.047

3.  Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

4.  Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Authors:  Samuel A Roiko; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-21       Impact factor: 3.922

Review 5.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

6.  Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression.

Authors:  Bridget L Morse; Gurkishan S Chadha; Melanie A Felmlee; Kristin E Follman; Marilyn E Morris
Journal:  Am J Drug Alcohol Abuse       Date:  2017-06-29       Impact factor: 3.829

7.  Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Authors:  Marilyn E Morris; Bridget L Morse; Gloria J Baciewicz; Matthew M Tessena; Nicole M Acquisto; David J Hutchinson; Robert Dicenzo
Journal:  J Clin Toxicol       Date:  2011-11-10

8.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

9.  Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells.

Authors:  Wing Ki Lam; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-12-01       Impact factor: 3.922

10.  Brain extracellular γ-hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses.

Authors:  Samuel A Roiko; Nisha Vijay; Melanie A Felmlee; Marilyn E Morris
Journal:  Pharm Res       Date:  2013-01-15       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.